Pharmaceutical - Alexion Pharmaceuticals


Current filters:

Alexion Pharmaceuticals

Popular Filters

Alexion inks deal with Moderna for rare diseases; “deal of the year” say analysts

Alexion inks deal with Moderna for rare diseases; “deal of the year” say analysts


US drugmaker Alexion Pharmaceuticals has signed an exclusive strategic agreement with privately-held…

Alexion PharmaceuticalsLicensingModerna TherapeuticsPharmaceuticalRare diseases

Citing “unreasonable price,” New Zealand declines eculizumab funding

Citing “unreasonable price,” New Zealand declines eculizumab funding


New Zealand’s Pharmaceutical Management Agency PHARMAC has declined the funding application for eculizumab…

Alexion PharmaceuticalsAsia-PacificeculizumabGlaxoSmithKlineHematologyNew ZealandPharmaceuticalPricingRare diseasesRevoladeSoliris

Alexion's Soliris gets approval in Japan for rare disorder


The Ministry of Health, Labor and Welfare (MHLW) in Japan has approved Soliris (eculizumab) from US drugmaker…

Alexion PharmaceuticalsAsia-PacificPharmaceuticalRare diseasesRegulationSoliris

Deal between Ensemble and Alexion will target ultra-rare disorders


USA-based drug discovery firm Ensemble Therapeutics has announced the initiation of a drug discovery…

Alexion PharmaceuticalsBiotechnologyEnsemble TherapeuticsNorth AmericaPharmaceuticalRare diseasesResearch

Orphan status for Alexion's Solaris


US drugmaker Alexion Pharmaceuticals (Nasdaq: ALXN) says that Soliris (eculizumab), the company's first-in-class…

Alexion PharmaceuticalsBiotechnologyEuropeNeurologicalPharmaceuticalRare diseasesRegulationSolaris

New Zealand declines Alexion's funding application for Solaris


New Zealand's Pharmaceutical Management Agency PHARMAC is seeking feedback on a proposal to decline the…

Alexion PharmaceuticalsAsia-PacificHealthcarePharmaceuticalPricingRare diseasesSolaris

Alexion tells shareholders to reject TRC's unsolicited mini-tender offer


US drugmaker Alexion Pharmaceuticals (Nasdaq: ALXN) says it has been notified of an , unsolicited "mini-tender"…

Alexion PharmaceuticalsMergers & AcquisitionsPharmaceutical

ASN meeting highlights Otsuka's tolvaptan' Alexion's Solaris and Roche's aleglitazar research


Japan's Otsuka Pharmaceutical (TYO: 4768) that the clinical trial results for tolvaptan, an investigational…

aleglitazarAlexion PharmaceuticalsNephrology and HepatologyOtsukaPharmaceuticalResearchRocheSolaristolvaptan

EMA orphan drug committee makes 16 recommendations at May meeting


The European Medicines Agency's Committee for Orphan Medicinal Products (COMP) adopted a total of 16…

Alexion PharmaceuticalsBiotechnologyeculizumabEuropePharmaceuticalRare diseasesRegulation

Alexion to buy Enobia Pharma for potential $1 billion


US drugmaker Alexion Pharmaceuticals (Nasdaq: ALXN) has reached agreement to acquire privately held Canadian…

Alexion Pharmaceuticalsasfotase alfaEnobia PharmaMergers & AcquisitionsPharmaceuticalRare diseases

Company Spotlight



Back to top